title: [Importance of prognostic factors in patients with chronic B-lymphocytic leukemia at the time of diagnosis].
abstract: BACKGROUND
  B-chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in the Western countries. Any routinely used staging system does not distinguish exactly the probable course of the disease at the time of diagnosis. Therefore the new prognostic factors, which help to assess the optimal therapeutic plan of patients, are searched intensively.
  
  
  RESULTS
  We evaluated 154 patients with the B-CLL at the time of diagnosis--133 of them were retrospectively divided into two groups--one with stable form and the other with progressive form of the disease. We compared these two groups of patients with some of the prognostic factors (absolute lymphocyte count, the level of C-reactive protein, lactatdehydrogenase, beta-2-microglobulin, tumour necrosis factor, the immunoglobulin levels, the expression of CD38, FMC7, surface immunoglobulins, the type of bone marrow infiltration, and the cytogenetic abnormalities (trisomy 12, del(13)(q14), del(17)(p13) a del(11)(q23)). We found higher absolute lymphocyte count, level of beta-2-mikroglobulin, tumour necrosis factor, expression of CD38, light chains lambda, lower expression of FMC7 and less frequent nodular type of bone marrow infiltration by the patients with progressive disease. The correlation of the cytogenetic abnormalities and the course of the disease or stage according to the RAI et al. [27] staging system were not significant may be due to the small number of evaluated patients and short period of follow up.
  
  
  CONCLUSIONS
  The routine evaluation of some risk factors in patients with B-chronic lymphocytic leukemia at the time of diagnosis helps to distinguish those with the probable more aggressive course of the disease and have the implication for the design of risk-adapted treatment strategies. The prognostic impact of the cytogenetic abnormalities and other risk factors has to be evaluated on larger group of patients during longer follow up period and repeated evaluations.
authors.affiliation: I. interní klinika Vseobecné fakultní nemocnice a 1. lékarské fakulty Univerzity Karlovy, U nemocnice 2, 128 08 Praha 2, Czech Republic. cmunt@vfn:cz
authors.forename: E
authors.initials: E
authors.lastname: Cmunt
authors.forename: K
authors.initials: K
authors.lastname: Michalová
authors.forename: L
authors.initials: L
authors.lastname: Sindelárová
authors.forename: J
authors.initials: J
authors.lastname: Karban
authors.forename: Z
authors.initials: Z
authors.lastname: Zemanová
authors.forename: S
authors.initials: S
authors.lastname: Kurková
authors.forename: J
authors.initials: J
authors.lastname: Brezinová
authors.forename: J
authors.initials: J
authors.lastname: Schwarz
authors.forename: Z
authors.initials: Z
authors.lastname: Bosáková
mesh_terms: D014408:Biomarkers, Tumor; D020732:Cytogenetic Analysis; D018450:Disease Progression; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors
chemical_list: D014408:Biomarkers, Tumor
vernacular_title: Význam prognostických faktorů pacientů s B-chronickou lymfatickou leukemií v dobĕ diagnózy.